Lemtrada

Type: Product
Name: Lemtrada
First reported 6 hours ago - Updated 6 hours ago - 1 reports

FDA Red Tape Blocks Effective Treatments

A dozen sunscreens sold abroad are more effective than those available here, but U.S. regulators have yet to OK them. A promising new MS drug, Lemtrada, has been in use for years in Europe yet American officials have rejected it. And it can take 15 years ... [Published NewsMax.com - 6 hours ago]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

MSology at ACTRIMS-ECTRIMS – BOSTON 2014

The largest event on MS research will be the joint meeting of ACTRIMS-ECTRIMS, which will be held from September 10-13. MSology will be attending this year’s meeting in Boston. A lot of new information will be presented, so you can help us pick the ... [Published MSology - Aug 14 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Sanofi Appears To Be In The Early Stages Of An Earnings Rebound

Summary Patent expiries restrained earnings and share-price gains the last several years. Sales erosion stemming from generic copies are now mostly in the rear-view mirror. Investors seem a little late in recognizing the unfolding of an earnings recovery. ... [Published Seeking Alpha - Aug 11 2014]
First reported Aug 10 2014 - Updated Aug 10 2014 - 1 reports

Anyone here having trouble paying for MS drugs? I have possible solution....

I’m new to this forum and decided to post this incase I might be able to help others. I have MS (for 13 yrs now) but am doing very well on LDN and the Dr Roy Swank diet, thank goodness!!…but a close friend of mine who also has MS was having great difficulties ... [Published HealthBoards - Aug 10 2014]
Entities: Lemtrada, Diet
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

MS market set to grow 4% annually

The multiple sclerosis (MS) market across the world's biggest pharma territories is set to grow by 4% annually over the next decade, according to analysts.Decision Resources Group says revenues in the therapy area will steady growth between now and 2023 ... [Published PMLive - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

New results for two novel therapies

Promising new results have now been published for two monoclonal antibody (MAb) drugs in development that may provide additional options over the next few years. MAbs are biological agents that target highly specific targets. MAbs currently used in MS ... [Published MSology - Aug 07 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Stocks To Watch: Sanofi SA Rights

Summary SA contributors highlight a stock to watch for unusual movement, share their bias (long/short) and brief comments. Stocks are listed alphabetically, and you can click on the contributors' name to read more articles by that author. Discuss today's ... [Published Seeking Alpha - Aug 01 2014]
Entities: Sanofi SA, Stocks, Lemtrada
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Sanofi Investing €700 Million Ahead Of Launches

Related Biotechnology, Pharmaceutical and Healthcare NewsSanofi is ramping up for several product launches in the next 12 months, including a next-generation basal insulin Toujeo, Lemtrada for multiple sclerosis, Cerdelga for Gaucher’s disease and Praluent ... [Published BioPortfolio - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

SANOFI: Solid sales and Business EPS(1) growth at -4-

(sBLA) seeking approval of Lemtrada(TM) (alemtuzumab) for the treatmentof relapsing forms of multiple sclerosis. A six-month review period wasassigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA inthe fourth quarter.At the end of July ... [Published Scottrade - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Multiple sclerosis treatment landscape has undergone dramatic changes during 2013

(live-PR.com) - The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen´s Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, ... [Published Live-PR.com - Jul 31 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Report: Over Half of MS Patients Treated With Tecfidera Have Experienced Minor Side Effects

Lemtrada and ocrelizumab will likely be reserved for aggressive/severe MSDecision Resources Group, a health care research firm located in Burlington, Mass., finds that more than half of audited patients with multiple sclerosis (MS) currently treated with ... [Published PT Community - Jul 23 2014]
First reported May 30 2014 - Updated May 31 2014 - 4 reports

US FDA accepts Genzyme's Lemtrada resubmission for review

The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.  A ... [Published PharmaBiz - May 31 2014]

Quotes

"Our solid second quarter performance reflects consistent execution of our growth strategy and allows us to slightly adjust upwards our 2014 financial guidance. This quarter, growth platforms represented more than 75% of our sales. Based on the solid momentum in our late stage pipeline, we are actively preparing for a wave of new product launches that will further redefine Sanofi as a biopharmaceutical leader."
than 2013 at CER(1), barring major unforeseen adverse Sanofi Chief Executive Officer, Christopher A Viehbacher "Our solid second quarter performance reflects consistent"
...a transformational new treatment for relapsing-remitting multiple sclerosis," said Norma Deri, M D , Hosptial Fernandez, Buenos Aires, Argentina. "The approval of Lemtrada is good news for people living with active MS, who are in need of additional treatment options that may offer greater efficacy."
Louise Makin, BTG's CEO commented: "We have made a good start to the financial year, with revenues across the business growing as expected. The controlled launch of Varithena® in the US reimbursed sector is progressing well and the first patients are scheduled for treatment this quarter. We are implementing plans to expand direct sales of TheraSphere® and the EKOS products in Europe and to expand the availability of the interventional oncology products in Asia. These activities, together with the continued contribution from our specialty pharmaceuticals business and the financial underpin from our royalties, means we are well positioned to deliver sustainable profitable growth."

More Content

All (82) | News (24) | Reports (0) | Blogs (44) | Audio/Video (0) | Fact Sheets (0) | Press Releases (13)
sort by: Date | Relevance
FDA Red Tape Blocks Effective Treatments [Published NewsMax.com - 6 hours ago]
New drugs to boost graft-versus-host disease tr... [Published Pharma Letter - Aug 15 2014]
New Drugs to Boost Graft-Versus-Host Disease Tr... [Published PharmaAsia - Aug 15 2014]
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
Sanofi Appears To Be In The Early Stages Of An ... [Published Seeking Alpha - Aug 11 2014]
Anyone here having trouble paying for MS drugs?... [Published HealthBoards - Aug 10 2014]
MS market to reach $20 billion in 2023 boosted ... [Published Pharma Letter - Aug 08 2014]
MS market set to grow 4% annually [Published PMLive - Aug 08 2014]
New results for two novel therapies [Published MSology - Aug 07 2014]
Sanofi Beats on Q2 Earnings, View Up on Strong ... [Published Zacks.com - Aug 01 2014]
Stocks To Watch: Sanofi SA Rights [Published Seeking Alpha - Aug 01 2014]
Sanofi Investing €700 Million Ahead Of Launches [Published BioPortfolio - Jul 31 2014]
Multiple sclerosis treatment landscape has unde... [Published Live-PR.com - Jul 31 2014]
SANOFI: Solid sales and Business EPS(1) growth ... [Published Virtual Strategy Magazine - Jul 31 2014]
SANOFI: Solid sales and Business EPS(1) growth ... [Published Scottrade - Jul 31 2014]
SANOFI: Solid sales and Business EPS(1) growth ... [Published Scottrade - Jul 31 2014]
Report: Over Half of MS Patients Treated With T... [Published PT Community - Jul 23 2014]
7/20/14 - Genzyme's Lemtrada Approved in Argent... [Published Pharmacy Choice - Jul 20 2014]
BTG PLC : Interim Management Statement [Published Investegate - Jul 16 2014]
New MS drug Lemtrada approved for use in Scotland [Published MS News - Jul 07 2014]
Argentina approves Genzyme’s Lemtrada for multi... [Published Pharmaceutical Technology - Jul 02 2014]
Genzyme gets approval for Lemtrada in Argentina... [Published PBR - News - Jul 02 2014]
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Genzyme Press Release - Jun 30 2014]
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Business Wire Health News - Jun 30 2014]
Lemtrada: Long term data on safety and efficacy... [Published MS News - Jun 26 2014]
AAN 2014 – New MS treatment studies: Part II [Published MSology - Jun 12 2014]
FDA accepts to review Genzyme’s Lemtrada resubm... [Published PBR - News - Jun 02 2014]
Alemtuzumab approved in the UK...Let the Europe... [Published Multiple Sclerosis Research - May 31 2014]
US FDA accepts Genzyme's Lemtrada resubmission ... [Published PharmaBiz - May 31 2014]
Genzyme Announces: FDA Accepts Its Resubmitted ... [Published MS News - May 30 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
The largest event on MS research will be the joint meeting of ACTRIMS-ECTRIMS, which will be held from September 10-13. MSology will be attending this year’s meeting in Boston. A lot of new information will be presented, so you can help us pick the ...
Anyone here having trouble paying for MS drugs?... [Published HealthBoards - Aug 10 2014]
I’m new to this forum and decided to post this incase I might be able to help others. I have MS (for 13 yrs now) but am doing very well on LDN and the Dr Roy Swank diet, thank goodness!!…but a close friend of mine who also has MS was having great difficulties ...
New results for two novel therapies [Published MSology - Aug 07 2014]
Promising new results have now been published for two monoclonal antibody (MAb) drugs in development that may provide additional options over the next few years. MAbs are biological agents that target highly specific targets. MAbs currently used in MS ...
New MS drug Lemtrada approved for use in Scotland [Published MS News - Jul 07 2014]
The new MS drug Lemtrada (also known as alemtuzumab) has received a stamp of approval from Scottish Medicines Consortium (SMC). This means it will be made available on the NHS in Scotland for people with active relapsing remitting MS . Major step ...
Genzyme gets approval for Lemtrada in Argentina... [Published PBR - News - Jul 02 2014]
Genzyme has secured approval from Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) for its Lemtrada (alemtuzumab) to treat patients with multiple sclerosis. ...
1 2 3 4 5 6 7 8 9

Press Releases

sort by: Date | Relevance
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Genzyme Press Release - Jun 30 2014]
Genzyme’s Lemtrada Resubmission Accepted for Re... [Published Genzyme Press Release - May 30 2014]
Genzyme’s Lemtrada Resubmission Accepted for Re... [Published Sanofi.com - Last press releases - May 30 2014]
Genzyme’s Lemtrada Recommended for Reimbursemen... [Published Genzyme Press Release - May 28 2014]
Sanofi: Slowing of Brain Atrophy and Reductions... [Published GlobeNewswire: Advertising News - Apr 30 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.